Most cited papers from Temple University Health System
What are the most cited papers from Temple University Health System?
The most cited paper from Temple University Health System is "Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer" (H. Borghaei et al., 2015), with 9,557 citations. Next come "Integrated genomic analyses of ovarian carcinoma" (8,268) and "Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018" (6,760).
Showing 50 of 60 papers. Every paper with more than 1,637 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer H. Borghaei et al. · New England Journal of Medicine | 27 Sep 2015 | 9,557 |
| 2 | Integrated genomic analyses of ovarian carcinoma Debra Bell et al. · Nature | 28 Jun 2011 | 8,268 |
| 3 | Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 Lorenzo Galluzzi et al. · Cell Death and Differentiation | 23 Jan 2018 | 6,760 |
| 4 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) Daniel J. Klionsky et al. · Autophagy | 2 Jan 2016 | 6,023 |
| 5 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Robert John Motzer et al. · New England Journal of Medicine | 25 Sep 2015 | 5,972 |
| 6 | Comprehensive molecular profiling of lung adenocarcinoma Eric A. Collisson et al. · Nature | 8 Jul 2014 | 5,968 |
| 7 | Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer Joan H. Schiller, David T. Harrington, Chandra Prakash Belani et al. · New England Journal of Medicine | 10 Jan 2002 | 5,010 |
| 8 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Robert John Motzer et al. · New England Journal of Medicine | 21 Mar 2018 | 4,756 |
| 9 | The 2015 World Health Organization Classification of Lung Tumors William David Travis, Elisabeth M. Brambilla, Andrew Gordon Nicholson et al. · Journal of Thoracic Oncology | 21 Aug 2015 | 4,651 |
| 10 | Tolerance of normal tissue to therapeutic irradiation Bahman Emami, Jacqueline Lyman, Adam S. Brown et al. · International Journal of Radiation Oncology*Biology*Physics | May 1991 | 4,510 |
| 11 | Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors George D. Demetri et al. · New England Journal of Medicine | 15 Aug 2002 | 4,425 |
| 12 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms Joseph David Khoury et al. · Leukemia | 22 Jun 2022 | 4,204 |
| 13 | Comprehensive genomic characterization of squamous cell lung cancers Peter S. Hammerman et al. · Nature | 7 Sep 2012 | 4,071 |
| 14 | A framework for advancing our understanding of cancer-associated fibroblasts Erik A. Sahai et al. · Nature reviews. Cancer | 24 Jan 2020 | 3,962 |
| 15 | Inflammation and Cancer: Triggers, Mechanisms, and Consequences Florian R. Greten, Sergei I. Grivennikov · Immunity | Jul 2019 | 3,881 |
| 16 | The repertoire of mutational signatures in human cancer Ludmil B. Alexandrov et al. · Nature | 5 Feb 2020 | 3,854 |
| 17 | Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma Gary R. Hudes, Michael Anthony Carducci, Piotr Tomczak et al. · New England Journal of Medicine | 30 May 2007 | 3,671 |
| 18 | Comprehensive molecular characterization of clear cell renal cell carcinoma Chad J. Creighton et al. · Nature | 23 Jun 2013 | 3,603 |
| 19 | PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma Stephen Maxted Ansell, Alexander M. Lesokhin, Ivan Borrello et al. · New England Journal of Medicine | 6 Dec 2014 | 3,594 |
| 20 | Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Brian I. Rini et al. · New England Journal of Medicine | 16 Feb 2019 | 3,488 |
| 21 | Pan-cancer analysis of whole genomes Lauri A. Aaltonen et al. · Nature | 5 Feb 2020 | 3,360 |
| 22 | VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche Rosandra Natasha Kaplan et al. · Nature | Dec 2005 | 3,287 |
| 23 | Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer Arlene A. Forastiere, Helmuth Goepfert, Moshe H Maor et al. · New England Journal of Medicine | 26 Nov 2003 | 3,192 |
| 24 | Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden Matthew David Hellmann et al. · New England Journal of Medicine | 16 Apr 2018 | 3,185 |
| 25 | Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers Karoline B. Kuchenbaecker et al. · JAMA | 20 Jun 2017 | 2,963 |
| 26 | Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer Christopher J. Sweeney, Yu‐Hui Chen, Michael Anthony Carducci et al. · New England Journal of Medicine | 5 Aug 2015 | 2,915 |
| 27 | Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer Matthew David Hellmann et al. · New England Journal of Medicine | 28 Sep 2019 | 2,901 |
| 28 | Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children Alexander Edward Dela Cruz Drilon et al. · New England Journal of Medicine | 21 Feb 2018 | 2,827 |
| 29 | Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial Carole Fakhry, William H. Westra, S. Li et al. · JNCI Journal of the National Cancer Institute | 12 Feb 2008 | 2,814 |
| 30 | Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Mack Roach, Gerald E. Hanks, Howard D. Thames et al. · International Journal of Radiation Oncology*Biology*Physics | 24 Jun 2006 | 2,770 |
| 31 | First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer David Paul Carbone et al. · New England Journal of Medicine | 21 Jun 2017 | 2,602 |
| 32 | CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Andy Trotti, A. D. Colevas, A. Setser et al. · Seminars in Radiation Oncology | Jul 2003 | 2,589 |
| 33 | The R.E.N.A.L. Nephrometry Score: A Comprehensive Standardized System for Quantitating Renal Tumor Size, Location and Depth Alexander Kutikov, Robert G. Uzzo · The Journal of Urology | 18 Jul 2009 | 2,426 |
| 34 | Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer Robert Allen Burger, Mark F. Brady, Michael A. Bookman et al. · New England Journal of Medicine | 28 Dec 2011 | 2,422 |
| 35 | Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy Răzvan Cristescu et al. · Science | 11 Oct 2018 | 2,408 |
| 36 | Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 Bruce J. Giantonio, Paul J. Catalano, Neal J. Meropol et al. · Journal of Clinical Oncology | 18 Apr 2007 | 2,283 |
| 37 | Stereotactic body radiation therapy: The report of AAPM Task Group 101 Stanley Benedict et al. · Medical Physics | 14 Jul 2010 | 2,228 |
| 38 | A severe combined immunodeficiency mutation in the mouse Gayle C. Bosma, R. Philip Custer, Melvin J. Bosma · Nature | Feb 1983 | 2,218 |
| 39 | The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase Thomas F. Franke, Sung‐Il Yang, Tung O. Chan et al. · Cell | Jun 1995 | 2,033 |
| 40 | The importance of glutathione in human disease Danyelle M. Townsend, Kenneth D. Tew, Haïm Tapiero · Biomedicine & Pharmacotherapy | May 2003 | 2,015 |
| 41 | Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival James A. Bonner, Paul M. Harari, J. Giralt et al. · The Lancet Oncology | 12 Nov 2009 | 1,984 |
| 42 | The Immunological Genome Project: networks of gene expression in immune cells Tracy S P Heng et al. · Nature Immunology | 18 Sep 2008 | 1,980 |
| 43 | KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma Michael Wang et al. · New England Journal of Medicine | Apr 2020 | 1,874 |
| 44 | Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer Steven J. Cohen, Cornelis J.A. Punt, Nicholas O. Iannotti et al. · Journal of Clinical Oncology | 30 Jun 2008 | 1,863 |
| 45 | Sotorasib for Lung Cancers with KRAS p.G12C Mutation Ferdinandos Skoulidis et al. · New England Journal of Medicine | 4 Jun 2021 | 1,862 |
| 46 | The Tuberous Sclerosis Complex Peter B. Crino, Katherine L. Nathanson, Elizabeth P. Henske · New England Journal of Medicine | 27 Sep 2006 | 1,793 |
| 47 | Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology Al B. Benson et al. · Journal of the National Comprehensive Cancer Network | Mar 2021 | 1,789 |
| 48 | Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy Woonyoung Choi, Sima P. Porten, Seungchan Kim et al. · Cancer Cell | Feb 2014 | 1,778 |
| 49 | Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology Jaffer A. Ajani et al. · Journal of the National Comprehensive Cancer Network | Feb 2022 | 1,772 |
| 50 | PISCES: a protein sequence culling server Guoli Wang, Roland L. Dunbrack · Bioinformatics | 11 Aug 2003 | 1,770 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.